Incara

The Incara lives in the demersal, brackish environment.

Incara's catalytic antioxidants, and is a continuation of a Phase I grant from last year. The Phase II grant of $375,000 has been awarded for this year, and an additional $375,000 has been contingently approved for the following year. More

Icon INCARA has not set their status 1. About Me 2. Topics 3. Posts 4. Blog 5. More

Incara closes $10.3 million financing. = Publication: Pharma Marketletter Publication Date: 26-APR-04 Format: Online - approximately 177 words Delivery: Immediate Online Access Full Article Title: Incara closes $10.3 million financing. More

Incara Pharmaceuticals and Indevus Pharmaceuticals of Lexington, MA, are outlicensing the beta-blocker bucindolol to ARCA Discovery of Aurora, CO. Bucindolol was previously under development by RTP-based Incara for the treatment of heart failure, but development was discontinued in 1999. More

Incara Pharmaceuticals says it will tout a possible treatment for Lou Gehrig's disease at an international forum on Wednesday. Dr. More

Incara Pharmaceuticals Corporation 4401 Research Commons, Ste 200 Research Triangle Park, North Carolina 27709 Incara Pharmaceuticals Corporation is focused on a new class of disease-modifying small molecules, the catalytic antioxidants. More

Incara to revise testing program for first drug candidate ...Incara Pharmaceuticals Corp. announced Monday that it will revise the Phase I clinical... More

Incara's stock price was at 10 cents when the Nasdaq National Market closed Tuesday. Its 52-week range was 8 cents to $1.90. More

Incara Pharmaceuticals Corp acquires remaining interest in Aeolus Pharmaceuticals Inc = US - Incara Pharmaceuticals Corp (IP) acquired the remaining ##% interest, that it did not already own, in Aeolus Pharmaceuticals Inc, a provider of research and development services and More

Incara's catalytic antioxidant compound, AEOL 10150, has demonstrated efficacy in an animal model of ALS, and models of other neurodegenerative diseases. In recent experiments in a transgenic mouse model of ALS, the survival time period after symptom onset for the AEOL 10150-treated group was 2. More

Incara Pharmaceuticals Corporation (BULLETIN BOARD: ICRA ) announced the presentation of results for its catalytic antioxidant compound, AEOL 10150, in a preclinical model of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). John P. Crow, Ph.D. More

Bennett Love, Incara VP of corporate planning said, while he would look toward partnering up with a company, a sale was possible. "We will look at all the options based on Piper Jaffray's findings," he said. On the Nov. More

* Incara Announces Results for Third Quarter of Fiscal 1999 * Microsoft, Government Officials Submit 'Findings of Fact' * James J. Waltke; Was Businessman, Ad Executive * Clinton Names Dan Herman Renberg as Member of Board of... More

Incara Pharmaceuticals Receives Fast Track SBIR Grant for Cancer Research from NIH RESEARCH TRIANGLE PARK, N.C. More

Incara Clears Toxicology Hurdle, Makes Initial Draw On $5 Million Financing RESEARCH TRIANGLE PARK, N.C. More

Incara said it intends to file an Investigational New Drug application for AEOL 10150 in the second quarter of 2004. More

Incara is in final preparation of an Investigational New Drug (IND) application to be filed with the FDA for treatment of ALS. Allowance of the IND by the FDA would permit Incara to initiate clinical trials. More

Incara in her own right is notable for being our youngest Shapeways member at 10 years old. Her model, Incaras first character is adorable and she modeled it herself! You can check out Rob and Incara's great models here. More

Possible Big Boost for Incara: FDA Grants Oprhan Drug Status for ALS Treatment Incara plans to file investigational drug application for fighting Lou Gehrig's disease sometime next year. Orphan drug treatment could mean additional support, incentives from FDA. 1. More

Home > Nationwide > More Info - Incara Pharmaceuticals CoE-mail this page Incara Pharmaceuticals Co = 79 T W Alexander Dr Durham, NC 27711 * (919) 485-8034 Be the first to More

Incara Begins Transition to Clinical Development Phase of Lead Molecule For ALS and Ushers in New Board of Directors to Manage Transition NEW YORK, April 30 /PRNewswire-FirstCall/ - Goodnow Capital, L.L.C. More

"The Board of Directors of Incara is pleased to have an individual with Dr. Crapo's record of leadership and accomplishments join as Incara's CEO," stated David C. Cavalier, Chairman of Incara. More

Common names

Incara in English
多鱗英卡塘鱧 in Mandarin Chinese
多鱗英卡塘鱧 in Unknown
多鳞英卡塘鳢 in Mandarin Chinese
多鳞英卡塘鳢 in Unknown

Custom Search